"Yes I agree if Brilacidin caused adverse reaction in compassionate use that would have to be reported."
Only to the FDA, not to the public.
The most common adverse event in the group of in extremis patients to whom brilacidin is administered under the expanded access program is likely to be death, which will (probably) be nothing to do with brilacidin.
Market Data 
Markets 
AI
